今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

奋楫扬帆正当时！第十八、十九届中国电影华表奖颁奖典礼将于5月23日隆重举行

北京 – 2023年5月16日，国家电影局宣布，由中共中央宣传部电影局（国家电影局）主办的第十八届、十九届中国电影华表奖颁奖典礼将于5月23日（星期二）晚在北京国家体育馆隆重举行。届时，将揭晓两届评选结果，表彰近年来取得突出成绩的优秀影片和电影工作者。

中国电影华表奖是中国电影政府奖，代表着中国电影最高荣誉，与中国电影金鸡奖、大众电影百花奖一起，始终吸引着电影工作者的积极参与和广大观众的热切关注。

时隔四年，华表奖颁奖典礼与全国电影工作者、全国电影观众再次喜相逢，可谓意义非凡。本次颁奖典礼主题为“奋楫扬帆正当时”，旨在激励广大电影工作者不忘初心、牢记使命，以昂扬的斗志和饱满的热情，创作更多思想精深、艺术精湛、制作精良的优秀电影作品，推动中国电影高质量发展。

据悉，本次华表奖评选工作坚持质量第一、强化精品意识，以思想精深、艺术精湛、制作精良为标准；坚持把社会效益放在首位、社会效益和经济效益相统一；坚持公开、公平、公正原则，严格标准、严格程序，优中选优、宁缺毋滥，集中评选出一批弘扬民族精神和时代精神，积极反映现实生活，深受广大观众喜爱的优秀作品。

第十八届、十九届中国电影华表奖的评选结果，充分体现了近年来中国电影创作的丰硕成果和发展进步，必将对推动中国电影高质量发展产生积极作用。

期待两届华表奖的精彩揭晓，让我们共同见证中国电影的辉煌成就！

新闻延伸：

• 本次华表奖颁奖典礼将邀请电影界代表共同出席，包括老一辈电影艺术家、电影界中坚力量和青年电影人等。
• 届时，CCTV-6电影频道将对红毯仪式、颁奖典礼进行全程直播，并于5月22日至23日推出大型融媒体直播活动，全景直击华表盛况。

附：

• 第十八届、十九届中国电影华表奖提名名单：https://zh.wikipedia.org/zh-cn/%E7%AC%AC18%E3%80%8119%E5%B1%86%E4%B8%AD%E5%9C%8B%E9%9B%BB%E5%BD%B1%E8%8F%AF%E8%A1%A8%E7%8D%8E